The signaling pathways mediating the phosphaturic actions of PTH are heavily disputed; while many in vitro and ex vivo investigations indicate that the IP3/PKC pathway down-stream of the PTH/PTHrP receptor (PTHR1) is of considerable importance, different forms of pseudohypoparathyroidism (PHP) are clearly caused by abnormal Gas signaling, indicating that the cAMP/PKA signaling pathway has a major role in renal phosphate handling. Consistent with these findings in rare genetic disorders, recent studies in mice have shown that the acute PTH-stimulated excretion of phosphate largely depends on cAMP/PKA signaling. However, mice engineered to express a mutant PTHR1 that fails to increase IP3/PKC formation in response to PTH (D/D mice) develop resistance towards prolonged PTH elevations, indicating that the long-term PTH-dependent regulation of renal phosphate excretion requires intact IP3/PKC signaling. Through signal-selective PTH analogs and genetically manipulated mice, we propose to further dissect the relative contribution of each second messenger pathway to acute and chronic PTH-dependent handling of renal phosphate excretion (Aim 1). We will furthermore determine whether desensitization of the cAMP/PKA pathway occurs with prolonged PTH stimulation, thus explaining the only transient phosphaturic effect of acute PTH injections (Aim 2). Lastly, through the use of PEGylated, signal-selective PTH analogs that are not filtered at the glomerular membrane, we will determine whether PTH acts at the brush-border membrane, at the base-lateral membrane, or at both membranes (Aim 3). Our experiments are expected to help in the development of PTH analogs or PTH mimetics that promote phosphate excretion, ideally without having major effects on calcium homeostasis, thus reducing the risk of extraosseous calcifications in patients with rare genetic disorders or earlier stage of chronic kidney disease (CKD), and lowering the circulating levels of fibroblast growth factor 23 (FGF23), which contribute to kidney disease progression and left ventricular hypertrophy, and probably early mortality in patients with end-stage renal disease.

Public Health Relevance

Defining the second messenger pathway at the PTH/PTHrP receptor that enhances urinary phosphate excretion will help in developing PTH analogs or small molecules with sustained phosphaturic properties. Besides allowing dissection of the molecular mechanisms involved in renal phosphate handling, such compounds could help treat hyperphosphatemic disorder, including earlier stages of chronic kidney disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK011794-50
Application #
9392548
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
50
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Grigelioniene, Giedre; Nevalainen, Pasi I; Reyes, Monica et al. (2017) A Large Inversion Involving GNAS Exon A/B and All Exons Encoding Gs? Is Associated With Autosomal Dominant Pseudohypoparathyroidism Type Ib (PHP1B). J Bone Miner Res 32:776-783
Roszko, Kelly L; Bi, Ruiye; Gorvin, Caroline M et al. (2017) Knockin mouse with mutant G?11 mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors. JCI Insight 2:e91079
Mitchell, Deborah M; J├╝ppner, Harald; Burnett-Bowie, Sherri-Ann M (2017) FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls. J Clin Endocrinol Metab 102:1151-1160
Li, Yuwen; Caballero, Daniel; Ponsetto, Julian et al. (2017) Response of Npt2a knockout mice to dietary calcium and phosphorus. PLoS One 12:e0176232
Leaf, David E; Jacob, Kirolos A; Srivastava, Anand et al. (2017) Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. J Am Soc Nephrol 28:1877-1885
Knab, Vanessa M; Corbin, Braden; Andrukhova, Olena et al. (2017) Acute Parathyroid Hormone Injection Increases C-Terminal but Not Intact Fibroblast Growth Factor 23 Levels. Endocrinology 158:1130-1139
Guo, Jun; Khatri, Ashok; Maeda, Akira et al. (2017) Prolonged Pharmacokinetic and Pharmacodynamic Actions of a Pegylated Parathyroid Hormone (1-34) Peptide Fragment. J Bone Miner Res 32:86-98
Balani, Deepak H; Ono, Noriaki; Kronenberg, Henry M (2017) Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J Clin Invest 127:3327-3338
Kim, Sang Wan; Lu, Yanhui; Williams, Elizabeth A et al. (2017) Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts. J Bone Miner Res 32:892-901
Ono, Noriaki; Kronenberg, Henry M (2016) Bone repair and stem cells. Curr Opin Genet Dev 40:103-107

Showing the most recent 10 out of 208 publications